🇮🇳 India Daybook: Lupin Gets USFDA Nod, BEL Bags ₹541 Cr Order; Retail Traders Plan Boycott

📍 REGULATORY APPROVAL

• Lupin: The pharmaceutical major has received USFDA approval for Sodium Zirconium Cyclosilicate for oral suspension. The drug, indicated for treating hyperkalaemia, targets a US market estimated at $568 million annually.

📍 ORDER WIN

• Bharat Electronics Ltd (BEL): The defense PSU secured additional orders worth ₹541 crore for communication equipment, electro-optics, and CBRN systems, further strengthening its revenue visibility.
• Zen Technologies: Bagged a fresh contract worth ₹295 crore from the Ministry of Defence for the supply of simulators.

📍 QUARTERLY RESULTS

• Vodafone Idea: The company reported a significantly narrowed consolidated loss of ₹3,754 crore for Q1 FY27, compared to a loss of ₹6,608 crore in the previous year. Revenue rose 6% to ₹11,689 crore.
• Lloyds Metals and Energy: Reported a massive 165% year-on-year surge in Q1 net profit to ₹1,726.6 crore, driven by a 209% jump in revenue.
• Kolte-Patil Developers: Swung to a net profit of ₹146.3 crore in the June quarter from a loss of ₹17 crore last year, with revenue growing 11-fold to ₹919.5 crore.
• Lumax Auto Technologies: Q1 net profit grew 109.2% YoY to ₹86.6 crore, while revenue increased by 32.9% to ₹1,363.6 crore.
• RHI Magnesita India: Reported an 83% YoY increase in Q1 net profit to ₹64.6 crore, with EBITDA margins improving to 13.6%.
• IFCI: Consolidated net profit for Q1 fell 16% YoY to ₹33.5 crore, as total income declined by nearly 20% to ₹358 crore.

📍 DIVIDEND

• Industrial and Prudential Investment Company: Today, August 12, is the record date for the final dividend of ₹120 per share (1200%) for the financial year 2025-26.

📍 CORPORATE ACTION

• Om Power Transmission: Shareholders have approved resolutions to create asset charges up to ₹1,000 crore and expand borrowing powers to facilitate future expansion.

📍 STOCKS IN FOCUS

• Retail Traders Boycott: Day traders have called for a nationwide boycott today, August 12, to protest the newly introduced Closing Auction Session (CAS) mechanism and high securities transaction taxes.
• Gland Pharma: Expected to see investor interest after reporting a Q1 net profit that is 41% higher than the corresponding quarter last year.

TAGS: India Daybook, Stocks in News, Corporate News, Stock Market, Company News

Tags: India Daybook Stocks in News Corporate News Stock Market Company News